Clinical Trials Logo

Survival Rate clinical trials

View clinical trials related to Survival Rate.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06095843 Completed - Survival Rate Clinical Trials

"Bony Changes Around Dental Implant in Free Fibular Graft Versus Non-Vascularized Iliac Crest Graft"

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the bony changes around dental implants in non-vascularized iliac crest grafts and free vascularized fibular flap in mandibular reconstruction. The main question it aims to answer are: • evaluate the bony changes around dental implants and it's survival rate in both groups

NCT ID: NCT03052621 Completed - Survival Rate Clinical Trials

Revisiting Omental Transposition in Locally Advance and Locally Recurrent Breast Cancer

Start date: January 1994
Phase: N/A
Study type: Observational

Locally advance breast cancer and extensive locoregional recurrence are still considered as complexity of reconstruction. Although previous studies concluded that omental transposition was considerably indicated in poor vascularity in irradiated tissue, secondary infection and large defect become the obstacles of local tissue flaps. While some centres showed the excellent healing of omental transposition. Meanwhile, many studies showed the preferable outcome in escalating radiotherapy in term of locoregional control. In the investigators' institute, omental transposition in breast cancer has been developed for twenty years. The only institute in Thailand enhanced using this procedure in order to closure of large primary breast cancer and chest wall recurrence. This procedure is undertaken by single surgeon (Dr. K.J.). The investigators' protocol of omental transposition is including preoperative chemotherapy, preoperative accelerated radiation up to 80 Gy, approval of breast cancer centre committee, and meticulous wound care including vacuum assisted wound dressing, non-adhesive dressing. As a result, survival time could be improved.

NCT ID: NCT00748358 Completed - Prostatic Neoplasms Clinical Trials

An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer

PROSUT
Start date: March 2008
Phase: Phase 2
Study type: Interventional

as second-line treatment in metastatic prostate cancer, the present study will investigate the efficacy of sunitinib (SUTENT) given orally at a dose of 37.5 mg continuously, for 6 cycles of 6 consecutive weeks .Patients who are still responders after 6 cycles will be treated until disease progression, pain progression, unacceptable toxicity or death due to any cause. Dose increase or reduction of 12.5 mg increments and change of schedule is recommended based on individual safety and tolerability. Follow-up for up to 1 year from the last dose of sunitinib.